{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:04:23Z","timestamp":1790269463804,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"\n Aims:<\/jats:title>\n The prognosis of acute myeloid leukemia (AML) in elderly patients is worse due to age and comorbidities. Lately, monotherapy with hypomethylating agents like azacitidine (Aza) has been used to prolong overall survival (OS) in AML patients. Herein, we present a retrospective study investigating treatment responses and OS of Aza in combination with etoposide (Eto) and cytarabine (ARA-C) in elderly.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n \n In this study, therapies and outcomes of 37 newly diagnosed AML patients, >60 years old, and ineligible for intensive chemotherapy were investigated retrospectively. Patients were grouped according to the treatments they received as follows - Group 1: low-dose conventional therapies as hydroxyurea, low-dose ARA-C, or best supportive care (\n n<\/jats:italic>\n = 11); Group 2: Aza alone (\n n<\/jats:italic>\n = 6); Group 3: Aza in combination with Eto and ARA-C (Aza + Eto + ARA-C,\n n<\/jats:italic>\n = 20).\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n It was found that an Aza + Eto + ARA-C combination therapy had significantly better overall response rates (\n P<\/jats:italic>\n = 0.002). Combination group had significantly better OS than Group 1 (8 months vs. 1 month,\n P<\/jats:italic>\n < 0.001), the difference between combination and monotherapy was not significant. The OS was also associated with age and performance status, but the difference was still statistically significant after adjustment for these factors, especially for patients with younger age and better performance.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n We concluded that combination therapy of Aza with Eto and ARA-C increases response rates, and prolong survival for this poor prognosed patient group. We believe that larger controlled studies investigating Aza combinations with other antileukemic drugs will contribute to the development of tolerable treatment protocols for elderly AML patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/0973-1482.187369","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T09:03:38Z","timestamp":1531991018000},"page":"1105-1111","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience"],"prefix":"10.4103","volume":"14","author":[{"given":"Birgul","family":"Onec","sequence":"first","affiliation":[{"name":"Department of Hematology, Ankara Diskapi Y\u0131ld\u0131r\u0131m Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harika","family":"Okutan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Diskapi Y\u0131ld\u0131r\u0131m Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Albayrak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Diskapi Y\u0131ld\u0131r\u0131m Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra Saribacak","family":"Can","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Diskapi Y\u0131ld\u0131r\u0131m Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedat","family":"Aslan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Diskapi Y\u0131ld\u0131r\u0131m Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basak Unver","family":"Koluman","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Diskapi Y\u0131ld\u0131r\u0131m Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozge Soyer","family":"Kosemehmetoglu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Diskapi Y\u0131ld\u0131r\u0131m Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aynur","family":"Albayrak","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ankara Diskapi Y\u0131ld\u0131r\u0131m Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,9,7]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.leukres.2014.11.027","article-title":"Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy","volume":"39","author":"Erba","year":"2015","journal-title":"Leuk Res"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy for acute myeloid leukemia","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2010-01-267302","article-title":"A novel prognostic model in elderly patients with acute myeloid leukemia: Results of 909 patients entered into the prospective AML96 trial","volume":"116","author":"R\u00f6llig","year":"2010","journal-title":"Blood"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11864-011-0162-4","article-title":"Treatment of elderly acute myeloid leukemia patients","volume":"12","author":"Motyckova","year":"2011","journal-title":"Curr Treat Options Oncol"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V98.5.1302","article-title":"Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom medical research council AML11 trial","volume":"98","author":"Goldstone","year":"2001","journal-title":"Blood"},{"key":"R8-20260109","first-page":"121","article-title":"Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: An update","volume":"2","author":"Fenaux","year":"2008","journal-title":"Ecancermedicalscience"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/10428190903318329","article-title":"Report of a phase 1\/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes","volume":"51","author":"Borthakur","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/cncr.24373","article-title":"Outcomes and quality of care in acute myeloid leukemia over 40 years","volume":"115","author":"Alibhai","year":"2009","journal-title":"Cancer"},{"key":"R13-20260109","first-page":"1513","article-title":"Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches","volume":"91","author":"Deschler","year":"2006","journal-title":"Haematologica"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.162.14.1597","article-title":"The outcomes and costs of acute myeloid leukemia among the elderly","volume":"162","author":"Menzin","year":"2002","journal-title":"Arch Intern Med"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1002\/cncr.25281","article-title":"Questions regarding frontline therapy of acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.1989.7.9.1268","article-title":"On the value of intensive remission-induction chemotherapy in elderly patients of 65 years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group","volume":"7","author":"L\u00f6wenberg","year":"1989","journal-title":"J Clin Oncol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.1990.8.2.272","article-title":"Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly","volume":"8","author":"Tilly","year":"1990","journal-title":"J Clin Oncol"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2010.08082.x","article-title":"Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: Azacitidine compared with low dose ara-C","volume":"149","author":"Fenaux","year":"2010","journal-title":"Br J Haematol"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1097-0142(197607)38:1<36::AID-CNCR2820380107>3.0.CO;2-M","article-title":"A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia","volume":"38","author":"Levi","year":"1976","journal-title":"Cancer"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V48.3.331.331","article-title":"5-Azacytidine (NSC 102816): A new drug for the treatment of myeloblastic leukemia","volume":"48","author":"Vogler","year":"1976","journal-title":"Blood"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ajh.23654","article-title":"Azacitidine in untreated acute myeloid leukemia: A report on 149 patients","volume":"89","author":"Th\u00e9pot","year":"2014","journal-title":"Am J Hematol"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/hon.986","article-title":"Azacitidine has limited activity in 'real life' patients with MDS and AML: A single centre experience","volume":"30","author":"Ozbalak","year":"2012","journal-title":"Hematol Oncol"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-013-1940-9","article-title":"Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)","volume":"93","author":"Tawfik","year":"2014","journal-title":"Ann Hematol"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1182\/blood-2011-11-382226","article-title":"RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia","volume":"119","author":"Aimiuwu","year":"2012","journal-title":"Blood"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-2762","article-title":"Effect of cytarabine and decitabine in combination in human leukemic cell lines","volume":"13","author":"Qin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"e52695","DOI":"10.1371\/journal.pone.0052695","article-title":"Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia \u2013 A randomised SAL pilot study","volume":"7","author":"Krug","year":"2012","journal-title":"PLoS One"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood-2007-11-124602","article-title":"A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"112","author":"Faderl","year":"2008","journal-title":"Blood"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.leukres.2011.12.019","article-title":"Are low-intensity induction strategies better for older patients with acute myeloid leukemia","volume":"36","author":"Roboz","year":"2012","journal-title":"Leuk Res"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Blum","year":"2010","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201814050-00034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:01:40Z","timestamp":1786647700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201814050-00034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.187369","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}